Mixed-phenotype acute leukaemia: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Advanced, first line

Induction

3 optionsCompare side by side →

Acute lymphoblastic leukaemia-type induction in most patients; tyrosine kinase inhibitor for BCR::ABL1 disease; allogeneic transplant in first remission for adults and high-risk children.

The options, in plain words

ImatinibApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)

The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.

DasatinibApprovedSmall-molecule kinase inhibitor (BCR::ABL1, SRC)

Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all.

MRD / molecular residual disease testingEstablished

An ultra-sensitive blood test after surgery that detects leftover cancer months before a scan would.

Months of lead time over imaging
Enables escalation and de-escalation trials

Also referenced:Acute lymphoblastic leukaemiaAcute myeloid leukaemiaAllogeneic stem cell transplant (allo-SCT)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Imatinib all recorded rates →

Take with a meal and a large glass of water.

Dasatinib all recorded rates →

Side effect	Any grade	Grade 3+
Pleural effusion · CML long-term data	28%	-

Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

MRD / molecular residual disease testing

Sensitivity limited by cfDNA quantity
Lead time without proven intervention causes anxiety

Questions to ask about this decision

Between Imatinib, Dasatinib and MRD / molecular residual disease testing, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
Which side effects of Dasatinib are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (induction), which of the standard options do you recommend and why?
Why: Guideline options include: Acute lymphoblastic leukaemia-type induction in most patients; tyrosine kinase inhibitor for BCR::ABL1 disease; allogeneic transplant in first remission for adults and high-risk children.
Am I a candidate for Imatinib, Dasatinib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care